Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Rosiglitazone: a European regulatory perspective.

Blind E, Dunder K, de Graeff PA, Abadie E.

Diabetologia. 2011 Feb;54(2):213-8. doi: 10.1007/s00125-010-1992-5. Epub 2010 Dec 14. No abstract available.

PMID:
21153629
2.

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

Woodcock J, Sharfstein JM, Hamburg M.

N Engl J Med. 2010 Oct 14;363(16):1489-91. doi: 10.1056/NEJMp1010788. Epub 2010 Sep 23. No abstract available.

3.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

PMID:
20584880
4.

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.

Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD.

Eur Heart J. 2010 Apr;31(7):824-31. doi: 10.1093/eurheartj/ehp604. Epub 2010 Jan 29.

5.

The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.

Ren L, Li Y, Li Y, Tang R, Hu D, Sheng Z, Liu N.

Cell Biochem Funct. 2010 Jan;28(1):58-65. doi: 10.1002/cbf.1621.

PMID:
20029960
6.

Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.

Tao L, Wang Y, Gao E, Zhang H, Yuan Y, Lau WB, Chan L, Koch WJ, Ma XL.

Circ Res. 2010 Feb 5;106(2):409-17. doi: 10.1161/CIRCRESAHA.109.211797. Epub 2009 Nov 25.

7.

The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation.

Kilter H, Werner M, Roggia C, Reil JC, Schäfers HJ, Kintscher U, Böhm M.

Diabetes Obes Metab. 2009 Nov;11(11):1060-7. doi: 10.1111/j.1463-1326.2009.01097.x. Epub 2009 Sep 3.

PMID:
19732122
8.

Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway.

Zhang XJ, Xiong ZB, Tang AL, Ma H, Ma YD, Wu JG, Dong YG.

Clin Exp Pharmacol Physiol. 2010 Feb;37(2):156-61. doi: 10.1111/j.1440-1681.2009.05232.x. Epub 2009 Jun 29.

PMID:
19566839
9.

PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation.

Ren Y, Sun C, Sun Y, Tan H, Wu Y, Cui B, Wu Z.

Vascul Pharmacol. 2009 Aug-Sep;51(2-3):169-74. doi: 10.1016/j.vph.2009.06.004. Epub 2009 Jun 21.

PMID:
19540934
10.

Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.

Blasi ER, Heyen J, Hemkens M, McHarg A, Ecelbarger CM, Tiwari S.

PPAR Res. 2009;2009:237865. Epub 2009 Jun 11.

11.

Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation.

Festuccia WT, Laplante M, Brûlé S, Houde VP, Achouba A, Lachance D, Pedrosa ML, Silva ME, Guerra-Sá R, Couet J, Arsenault M, Marette A, Deshaies Y.

J Mol Cell Cardiol. 2009 Jul;47(1):85-95. doi: 10.1016/j.yjmcc.2009.04.011. Epub 2009 May 3.

PMID:
19397913
12.

Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies.

Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL.

Cardiovasc Diabetol. 2009 Apr 15;8:20. doi: 10.1186/1475-2840-8-20.

13.

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, Marchionni N.

Int J Cardiol. 2010 Aug 20;143(2):135-40. doi: 10.1016/j.ijcard.2009.01.064. Epub 2009 Mar 27.

PMID:
19328563
14.

A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.

Cobitz A, Zambanini A, Sowell M, Heise M, Louridas B, McMorn S, Semigran M, Koch G.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):769-81. doi: 10.1002/pds.1615.

PMID:
18613278
15.

Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway.

Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, Liu P.

Mol Cell Biochem. 2008 Oct;317(1-2):189-96. doi: 10.1007/s11010-008-9848-8. Epub 2008 Jul 4.

PMID:
18600431
16.

Rosiglitazone is cardioprotective in a murine model of myocardial I/R.

Mersmann J, Tran N, Zacharowski PA, Grotemeyer D, Zacharowski K.

Shock. 2008 Jul;30(1):64-8. doi: 10.1097/SHK.0b013e31815dbdc3.

PMID:
18562925
18.

Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs.

Lu L, Reiter MJ, Xu Y, Chicco A, Greyson CR, Schwartz GG.

Diabetologia. 2008 Apr;51(4):675-85. doi: 10.1007/s00125-008-0924-0. Epub 2008 Feb 5.

19.
20.

Standards of medical care in diabetes--2008.

American Diabetes Association..

Diabetes Care. 2008 Jan;31 Suppl 1:S12-54. doi: 10.2337/dc08-S012. No abstract available.

PMID:
18165335

Supplemental Content

Support Center